![David M. de Kretser](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David M. de Kretser
Technik-/Wissenschafts-/F&E-Leiter bei Paranta Biosciences Ltd.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Brendan Brown | M | - |
Paranta Biosciences Ltd.
![]() Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | - |
Ross Barrow | M | - |
Paranta Biosciences Ltd.
![]() Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | - |
John W. Raff | M | 74 |
Paranta Biosciences Ltd.
![]() Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | - |
Peter Hodgson | M | - |
Paranta Biosciences Ltd.
![]() Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | 8 Jahre |
Austin S. E. Miller | M | - |
Paranta Biosciences Ltd.
![]() Paranta Biosciences Ltd. Pharmaceuticals: MajorHealth Technology Paranta Biosciences Ltd. engages in the research and development of novel biotherapeutic. t develops PB01 (recombinant human follistatin-288) for the treatment of fibrotic and inflammatory diseases. The company was founded in 2011 and is headquartered in Richmond, Australia. | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Australien | 5 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- David M. de Kretser
- Persönliches Netzwerk